In July 2023, the FDA announced it was evaluating reports of suicidal thoughts and self-harm in patients taking semaglutide and liraglutide. The announcement followed a signal in EudraVigilance — the European Union's post-marketing database — and set off a year of coverage that ranged from measured to alarmist. By April 2024, the European Medicines Agency had concluded there was no causal link. The FDA reached a similar conclusion. And yet the investigation was never formally closed.
In 2026, that ambiguity is still there, quietly, in the background. This is a piece about what we actually know, why "unresolved" is not the same as "dangerous," and what good regulatory science looks like when the data is genuinely messy.
How the signal started
Post-marketing safety signals don't come from controlled trials. They come from voluntary reporting systems — patients and providers filing adverse event reports after a drug is on the market. The EudraVigilance database, which collects European reports, showed an elevated number of suicidality-related entries for semaglutide and liraglutide relative to what baseline rates might predict.
That sounds alarming. It is less alarming when you understand two things about how these databases work.
First: the Weber effect. When a drug becomes widely publicized — especially one as culturally prominent as Ozempic — reporting rates spike in the first years on the market regardless of actual adverse events. More scrutiny produces more reports. The spike is partially an artifact of attention.
Second: indication bias. GLP-1 medications are prescribed primarily for obesity and type 2 diabetes. Both conditions carry substantially elevated baseline rates of depression and suicidal ideation compared to the general population — independent of any medication. When you ask whether patients on a drug for obesity have elevated mental health events, you are already studying a group with elevated baseline mental health risk. Disentangling drug effect from indication effect requires randomized trial data, not a reporting database.
What the controlled trials showed
This is the critical data point that the 2023 coverage largely buried: the randomized controlled trials for these medications did not show elevated suicidality.
The STEP trials (semaglutide for obesity), the SCALE trials (liraglutide for obesity), the LEADER trial (liraglutide for cardiovascular outcomes), and the SURMOUNT trials (tirzepatide) all included psychiatric adverse event monitoring. None showed a statistically significant increase in suicidal ideation, self-harm, or completed suicide versus placebo.
The SELECT trial, which enrolled 17,604 patients with established cardiovascular disease, found no excess in neuropsychiatric events. This was a large, long-duration, placebo-controlled trial in a high-risk population — if semaglutide were causing suicidality at a population level, SELECT would likely have detected it.
What the EMA found — and what it actually said
In April 2024, the European Medicines Agency completed its review. The formal conclusion was that "a causal relationship between GLP-1 receptor agonists and suicidal and self-injurious thoughts cannot be established based on the available evidence." The EMA recommended no changes to product labeling for these drugs.
That is a specific regulatory conclusion. It is not "safe." It is "cannot establish causation." The distinction matters: absence of evidence is not evidence of absence, particularly when post-marketing observation periods are still short relative to the large number of patients now on these medications.
The EMA also noted several data limitations that prevented a more definitive ruling: the trials were not specifically designed to measure psychiatric endpoints with high sensitivity; the follow-up duration was limited (most pivotal trials ran under two years); and the patient populations had high baseline psychiatric comorbidity rates that complicated signal detection.
Why the FDA hasn't formally closed it
The FDA's position as of 2026 mirrors the EMA's: no causal link established, no label change required, continued post-marketing surveillance recommended. The investigation has not been "closed" in a formal sense because, technically, post-marketing surveillance is never closed — it is ongoing until a drug is withdrawn from the market.
What this means practically: the FDA is still receiving and reviewing adverse event reports, as it does for all approved medications. There is no active enforcement action, no boxed warning pending, and no new guidance to prescribers. The status is watch-and-wait, not alarm.
The groups that matter most for ongoing surveillance are pediatric patients (thinner data) and patients with pre-existing psychiatric conditions — both underrepresented in the original pivotal trials and both populations where prescribing is expanding as these medications become more mainstream.
The cultural read
One reason this signal is hard to communicate is that it arrived at exactly the wrong moment culturally. In 2023, semaglutide was the most talked-about pharmaceutical in a generation. The EudraVigilance reports broke through into mainstream coverage because the audience was primed for both celebration and concern about a drug that felt historic.
The actual regulatory story — "voluntary reporting signal, not replicated in controlled trials, indication bias is the likely explanation, continued surveillance warranted" — is accurate but unsatisfying. It requires understanding what post-marketing databases can and cannot tell you. That understanding is not widely shared.
In the absence of that context, "FDA investigating Ozempic and suicide" reads as more alarming than "FDA continues routine surveillance per standard post-approval protocol." Both sentences describe the same regulatory state.
What would actually close this
A prospective, adequately powered, randomized trial specifically measuring neuropsychiatric endpoints would provide the clearest answer. Such a trial would likely require tens of thousands of patients, multiple years of follow-up, and psychiatric outcome measurement at a level of granularity that the pivotal trials did not include.
No such trial is currently registered. The pharmaceutical companies are not incentivized to run one — the existing data is commercially favorable and a dedicated psychiatric endpoint trial introduces risk with limited upside. The question of who funds it, and whether it is ever prioritized, is an open one.
The more likely scenario: the signal fades as longer-duration real-world data accumulates and continues to show no excess. Not a formal closure — a gradual obsolescence of the concern as the evidence base grows.
A signal that was never replicated in controlled trials, explained by known methodological artifacts, and not acted on by either major regulatory body is technically open and practically resolved. The gap between those two states is where a lot of unnecessary fear lives.
This article is cultural reporting and regulatory analysis. It is not medical advice. Discuss any concerns about psychiatric effects of your medications with your prescribing clinician.